(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...
According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion ...
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...
In patients with high-risk myelodysplastic syndromes, hypomethylating agents are underutilized, particularly among older, female and non-White patients. Among patients with high-risk myelodysplastic ...
Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...
ESA treatment in lower-risk MDS patients is linked to improved overall survival and quality of life. Avoiding red blood cell transfusions is associated with significantly better health-related quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results